Advanced Heart Care, LLC | Bridgewater, NJ
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Serum high-sensitivity C-reactive protein (hs-CRP) greater than equal to 2 milligrams per liter (mg/L) at screening (visit 1) Disease specific - cardiovascular
At least one of the following:
Diagnosis of heart failure (New York Heart Association [classification] [NYHA] Class II-IV).
Left ventricular ejection fraction (LVEF) greater than 40 percentage (%) documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (e.g., myocardial infarction [MI] or heart failure [HF] hospitalisation).
Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:
Left atrial (LA) volume index greater than 34 milliliter per meter square (mL/m^2).
LA diameter greater than equal to 3.8 centimeter (cm).
LA length greater than equal to 5.0 cm.
LA area greater than equal to 20 cm square.
LA volume greater than equal to 55 milliters (mL).
Intraventricular septal thickness greater than equal to 1.1 cm.
Posterior wall thickness greater than equal to 1.1 cm.
Left ventricular (LV) mass index greater than equal to 115 grams per meter square (g⁄m^2 ) in men or greater than equal to 95 g⁄m^2 in women.
E/e' (mean septal and lateral) greater than equal to 10.
e' (mean septal and lateral) less than 9 centimeter per second (cm/s).
No heart failure hospitalisations or urgent heart failure visits between screening (visit 1) and randomisation (visit 2).
Exclusion criteria
Medical conditions - cardiovascular
Medical conditions - infections/immunosuppression
Primary purpose
Allocation
Interventional model
Masking
5,600 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Novo Nordisk
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal